

California COVID-19 Vaccination Program Update

Weekly Wrap Up – February 25, 2022

COVID-19 Therapeutics Update

Available Outpatient Therapies at Each Disease Stage

Treatment Options	SARS-CoV-2 Negative (-) <i>Prophylaxis</i>		SARS-CoV-2 Positive (+) <i>Treatment</i>
	Not Exposed	Exposed	Mild Illness or Moderate Illness
	Long-Acting Monoclonal Antibody <ul style="list-style-type: none"> Tixagevimab /cilgavimab (EVUSHELD) 	Monoclonal Antibodies <ul style="list-style-type: none"> Bamlanivimab/etesevimab Casirivimab/imdevimab (REGEN-COV) 	Monoclonal Antibodies <ul style="list-style-type: none"> Bamlanivimab/etesevimab Casirivimab/imdevimab (REGEN-COV) Sotrovimab Bebtelovimab Antivirals <ul style="list-style-type: none"> Nirmatrelvir/ritonavir (PAXLOVID) Molnupiravir (LAGEVRIO) Remdesivir (VEKLURY)

The red circle indicates: Not effective against Omicron; as of January 24, not authorized for use in any USA state

New Monoclonal Antibody: Bebtelovimab

The U.S. Food and Drug Administration (FDA) has issued an [Emergency Use Authorization \(EUA\) for the emergency use of Bebtelovimab](#) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in **adults and pediatric patients (12 years of age and older weighing at least 40 kg):**

- with positive results of direct SARS-CoV-2 viral testing, and
- who are at high risk for progression to severe COVID-19, including hospitalization or death, and
- for whom alternative COVID-19 treatment options approved or authorized by FDA

are not accessible or clinically appropriate.

Dosage: 175 mg single intravenous injection over at least 30 seconds. Give as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset.

Pharmacokinetics: No expected drug interactions, renal or hepatic impairment concerns, or bodyweight dosing adjustments

Clinical Outcome Data: Still being studied; phase 1/2 studies suggest similar safety profile to other monoclonals

Resources

Because COVID-19 therapeutics are a rapidly changing area of pandemic response, we encourage all providers to regularly check for updates on variant resistance, eligible populations, and treatment guidelines

Best resources for up-to-date information:

- Therapeutic Locator (HHS): [COVID-19 Therapeutics Locator \(arcgis.com\)](https://arcgis.com)
- NIH Treatment Guidelines: [COVID-19 Treatment Guidelines \(nih.gov\)](https://nih.gov)
- ASPR/HHS website: [COVID-19 Therapeutics | HHS/ASPR](https://hhs.gov)
- Side-by-side comparison table for specific drugs: [Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 \(hhs.gov\)](https://hhs.gov)
- CDPH COVID-19 Treatments site (information for patients and providers): [COVID-19 Treatments \(ca.gov\)](https://ca.gov)

Healthcare Provider Fact Sheets:

- [Paxlovid](#), [Sotrovimab](#), [Bebtelovimab](#), [Remdesivir](#) (here for patients <12 years of age), [Molnupiravir](#), and [Evusheld](#)

Moderna Smaller Vials

Moderna plans to make smaller vials of COVID-19 vaccines that may start shipping in April. These vials will be 5 doses per vial. The smaller vials will help reduce waste and support smaller providers.

Provider FAQ of the Week

The [California COVID-19 Vaccination Program Provider FAQs](#) are currently in their **60th**

iteration, updated weekly to answer new and relevant questions.

FAQ of the Week: *Where can COVID-19 vaccine Providers view a visual of COVID-19 vaccine timing by age?*

A: CDPH created a new job aid that outlines vaccine timing by age for both immunocompromised and immunocompetent individuals. Please view the COVID-19 Vaccine Timing by Age flow chart [here](#).

[Full list of Provider FAQs](#)

Pfizer COVID-19 Vaccine Medical Updates & Training Sessions

Please attend one of the following training sessions:

- [Tuesday, March 1 at 12PM](#) | Password: svU8YkF58Qc
- [Wednesday, March 2 at 9AM](#) | Password: 3jJ2WJMgeb8
- [Thursday, March 3 at 9AM](#) | Password: 4UBrwQDva77
- [Tuesday, March 8 at 12PM](#) | Password: yMMMMnf5U44
- [Wednesday, March 9 at 9AM](#) | Password: 2nWpjWa5H8B
- [Thursday, March 10 at 9AM](#) | Password: YMeTxT4qf43

More sessions listed! For the full list of Pfizer training sessions, please click [here](#).

myCAvax Updates

myCAvax Release 23 Update

Release 23 did not go live on Thursday, February 24. Please see [this communication](#) for further details and stay tuned for updates on when this release will be scheduled.

API Access

For users that interact with the Salesforce API: Starting at 5:00 PM on February 28th, the myCAvax team will be implementing a new API Access Control configuration. API's are typically used for program-to-program interactions or custom automation. This will only impact you or your organization if you created custom integrations with applications in your environment.

If your group does not use APIs there will be no impact to your My Turn or myCAvax experience. Going forward, only specific applications, profiles, and users who have been approved and whitelisted by the Security Team will be able to access myCAvax via API.

If you or your group use a locally built application or leverage a service account to connect to myCAvax or My Turn via API, please reach out to the myCAvax Help Desk, myCAvax.HD@accenture.com, as soon as possible to mitigate any impact to your workflows or business processes

Useful Resources

- [NEW COVID-19 Vaccine Timing by Age Chart](#)
 - [NEW Boosters for Aging Adults Poster](#)
 - [Upcoming Expiration Dates](#)
 - [Vaccine Administration Checklist](#)
 - [Preventing Vaccine Administration Errors](#)
 - [Reporting Doses Spoiled, Expired, or Wasted \(including Moderna booster doses\)](#)
 - [Receiving Redistributed Small Orders](#)
 - [Protect Kids with COVID-19 Vaccine Infographic](#)
 - [Summary of COVID-19 Vaccine Eligibility Guidance](#)
 - [COVID-19 Vaccine Product Guide](#)
 - [CDPH COVID-19 Treatments Webpage](#)
-

Support Opportunities

Provider Office Hours

Please attend our weekly webinars to hear updates from the COVID-19 Vaccination Program and have your questions answered.

- [Fridays 9–10 AM](#) (Password: Immunize!)
- [Archived Sessions | Frequently Asked Questions](#)

My Turn & myCAvax Office Hours for LHDs and Providers

- [Every Monday at 12:00 PM](#) (Password: Immunize!)

COVID Call Center for Providers

- For Program information: email covidcallcenter@cdph.ca.gov or call (833) 502-1245 (Monday – Friday, 8AM–6PM)

myCAvax Help Desk

- For technical issues (password resets, etc.): email myCAvax.HD@accenture.com or call (833) 502-1245, option 3 (Monday – Friday 7AM – 7PM, Saturday – Sunday)

8AM – 1PM)

- System related training materials are available via the Knowledge Center in myCAvax and at EZIZ.org/COVID

My Turn Help Desk

- Onboarding: email myturnonboarding@cdph.ca.gov
 - Technical support for My Turn Clinic: email MyTurn.Clinic.HD@Accenture.com or call (833) 502-1245, option 4 (Monday – Friday 7AM – 7PM, Saturday – Sunday 8AM–1PM).
 - [Job aids, demos and training opportunities](#)
-

[View Archived Messages](#)



Vaccinate ALL 58

Together we can end the pandemic.

COVID-19 Vaccination Program